Key NSCLC Data From the 2018 World Lung Cancer Conference - prIME Oncology
prIME Clinical Update
prIME Clinical Update

Key NSCLC Data From the 2018 World Lung Cancer Conference

Critical Analysis and Practical Application From Toronto

Not a member of My prIME? Join now for instant access.

Explore the latest trial data from the 2018 Annual World Lung Cancer Conference in Toronto. Experts in NSCLC discuss and analyze new data on immunotherapy and targeted therapy options and their potential impact on clinical practice.

Interactive Presentation

Interactive Presentation

CME

CME

0.5 AMA PRA Category 1 Credits™

CE

CE

0.5 Contact Hours

Release Date

Release Date

Sep 28, 2018

Expiration Date

Sep 28, 2019

Immunotherapy

Featured Experts

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China
  • David Spigel, MD, Sarah Cannon Research Institute, Nashville, Tennessee, United States

Featured Topics

Abstract #PL02.01: Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: Updated results from PACIFIC

Abstract #OA01.07: Updated results of a phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III NSCLC

Abstract #OA07.01: Phase II study of pembrolizumab for oligometastatic non-small cell lung cancer following completion of locally ablative therapy

Abstract #OA05.05: Avelumab vs docetaxel for previously treated advanced NSCLC: Primary analysis of the phase 3 JAVELIN Lung 200 trial

Abstract #MA10.06: Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab

Targeted Therapy

Featured Experts

  • Patrick Forde, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
  • Suresh Ramalingam, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topics

Abstract #PL02.03: Brigatinib vs crizotinib in patients with ALK inhibitor-naïve advanced ALK+ NSCLC: First report of a phase 3 trial (ALTA-1L)

Abstract #OA02.03: Clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: Phase 2 study cohort EXP-6

Abstract #MA15.03: D-L1 expression in untreated EGFRm advanced NSCLC and response to osimertinib and SoC EGFR-TKIs in the FLAURA trial

Abstract #OA02.01: Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC)

Abstract #OA02.02: Safety and preliminary clinical activity of ropotrectinib (TPX-0005), a ROS1/TRK/ALK inhibitor, in advanced ROS1 fusion-positive NSCLC

  • Tony Mok, MD, FRCPThe Chinese University of Hong Kong
    Hong Kong, China
  • Patrick Forde, MDSidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • David Spigel, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States

The information in this activity is intended for medical, surgical, and radiation oncologists, pulmonologists, oncology fellows, nurse practitioners, nurses, and other healthcare professionals involved in the treatment of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

Clinicians:

  • Discuss key data from the 2018 World Lung Cancer Conference
  • Apply key data from the 2018 World Lung Cancer Conference to clinical practice, as appropriate

Nurses:

  • Identify key findings from major lung cancer clinical trials presented at international symposia
  • Incorporate relevant new data into daily clinical practice

This educational activity is supported by grants from AstraZeneca; Merck and Co, Inc.; and Takeda Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


prIME Oncology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

prIME Oncology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 0.5 contact hours.

The criteria for successful completion include attending the full program and completing the evaluation.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Forde has disclosed that he has received consulting fees from AstraZeneca. He has also received research funding (to institution) from AstraZeneca/Medimmune, Bristol-Myers Squibb, Kyowa, and Novartis Oncology. He also disclosed his role as consultant and advisory board participation for AstraZeneca/Medimmune and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mok has disclosed board membership with ASCO, Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Ltd., Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Therapy Society (HKCTS), Hutchison Chi-Med, IASLC, and St. Stephen’s College & Prep School Hong Kong. He has also disclosed consulting fees for advisory boards and public lectures from AstraZeneca; ACEA Biosciences, Inc; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eli Lilly; Fishawack Facilitate Ltd; Hengrui Therapeutics Inc.; Hutchison Chi-Med; Ignyta, Inc.; Janssen; Merck Serono, MSD; Novartis; OncoGenex Pharmaceuticals, Inc.; OrigiMed; Pfizer; Roche/Genentech; Sanofi-Aventis R&D; SFJ Pharmaceutical; Takeda Oncology; Vertex Pharmaceuticals; and Yuhan Corporation. He has disclosed independent contracting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals, and Xcovery. He has disclosed ownership interest in Hutchison Chi-Med and Sanomics Ltd. He has disclosed speaking and teaching at public lectures or conference symposia for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Taiho, and Takeda Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ramalingam has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Spigel has disclosed that he has received consulting fees on behalf of his institution from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Lilly, Novartis, and Pfizer. He also disclosed receipt of research funding to his institution from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Genentech/Roche, Lilly, Merck, Novartis, Oncogenex, OncoMed, Peregrine Pharmaceuticals, Pfizer, and Verastem. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.